12h
Zacks Investment Research on MSNHow to Play VKTX Stock Amid Manufacturing Deal With CordenPharmaShares of Viking Therapeutics VKTX gained more than 11% on Wednesday after the company announced that it had signed a broad ...
4h
Zacks Investment Research on MSNViking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to NoteViking Therapeutics, Inc. (VKTX) closed at $29.73 in the latest trading session, marking a +0.61% move from the prior day. The stock exceeded the S&P 500, which registered a loss of 0.91% for the day.
Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...
1d
Zacks.com on MSNVKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug SupplyThe deal provides Viking Therapeutics with a secured dedicated annual supply of both injectable and oral versions of its ...
Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I ...
1don MSN
Viking Therapeutics Inc.’s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a manufacturing ...
Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year ...
In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report). The ...
After Viking Therapeutics (VKTX) announced a multi-year manufacturing agreement with CordenPharma to support the commercialization of VK2735, ...
Today, Benzinga's options scanner spotted 8 options trades for Viking Therapeutics. This is not a typical pattern. The ...
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results